Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316849 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00316849: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00316849 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00316849, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving temsirolimus together with temozolomide and radiation therapy may kill more tumor cells.
Interventions
- RADIATION intensity-modulated radiation therapy
- OTHER pharmacological study
- RADIATION 3-dimensional conformal radiation therapy
- PROCEDURE adjuvant therapy
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316849
The ClinicalTrials.gov registry entry for NCT00316849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which intensity-modulated radiation therapy is the first listed.
NCT00316849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316849 about?
NCT00316849 is a clinical study titled "Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". This phase I trial is studying the side effects and best dose of temsirolimus when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell...
What is the current status of trial NCT00316849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00316849?
The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), pharmacological study (OTHER), 3-dimensional conformal radiation therapy (RADIATION), adjuvant therapy (PROCEDURE), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00316849?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.